Pacira BioSciences stock: H.C. Wainwright cuts target to USD 36.50

H.C. Wainwright cut its view on Pacira BioSciences on October 9, 2026, moving the rating from Buy to Neutral and lowering its price target to USD 36.50 from USD 38.00. Markets Insider reported that the change followed Pacira's agreement to be acquired by Viatris for cash.

The analyst firm viewed the transaction consideration and the premium for shareholders positively. At the same time, it cited slower Exparel volume growth and competitive uncertainty as reasons for a more cautious stance on Pacira as a standalone business.

Deal shifts the valuation frame

The announced transaction changes the central question for investors. Instead of valuing Pacira primarily on future commercial expansion, the market is increasingly focused on completion risk, the agreed cash consideration and the timetable for the proposed acquisition. The analyst action therefore reflects both company-specific operating concerns and the reduced scope for a separate growth valuation.

Lang & Schwarz quoted the stock at 32.50 euros on October 29, 2026, at 10:59:30 p.m. Berlin time. The quote was unchanged from the displayed previous close. No verified Xetra closing comparison is included because the checked German market data did not provide a usable dated Xetra basis.

Investors should distinguish the analyst opinion from the transaction outcome: a rating change does not itself determine whether the acquisition will close. The main watch points remain the formal conditions of the deal, regulatory or shareholder developments and the operating trend for Pacira's non-opioid pain products.

For a direct view of the latest available quote, see the real-time quote of Pacira BioSciences stock.

The broader US market context is available through the S&P 500 market overview.

More news and analyses on Pacira BioSciences stock.